New Article · When AI meets the institution – 5 min read

Read here

New Article · 5 min read

Read here

>

When AI Meets the Institution: Part 2

>

When AI Meets the Institution: Part 2

>

When AI Meets the Institution: Part 2

When AI Meets the Institution: Part 2

AI promises greater efficiency in healthcare, but who truly benefits? Explore why productivity gains depend on trust, fair distribution of value and the redesign of healthcare systems—not simply time saved.

Productivity is a bargain, not a number

AI business cases commonly convert minutes saved into monetary value. That arithmetic is easy and often fictitious. Time is not cash unless the organisation can aggregate it, redesign capacity and change a budget or outcome. Ten minutes saved across many clinicians may be valuable as reduced fatigue and better conversations while producing no cashable saving. That is still real value, but it is a different claim.

The deeper problem is distribution. Acemoglu and Johnson’s Power and Progress argues that technological gains are not automatically shared; institutions and bargaining power determine who benefits.[6] In healthcare, that question is unusually complex because patients, professionals, providers, commissioners, taxpayers and vendors may each create or capture different parts of the value.

Four forms of value

Value

Example

Common category error

Clinical

Earlier deterioration detection; fewer errors

Assuming model accuracy equals improved outcomes

Experiential

Less clerical work; clearer patient communication

Dismissing wellbeing because it is not cashable

Capacity

More appointments or faster turnaround

Assuming scattered minutes automatically form a usable session

Financial

Lower cost, avoided spend or additional revenue

Counting theoretical hours without changing staffing or demand

A credible business case therefore needs an explicit conversion mechanism. If documentation time falls, will rotas change, overtime fall, visits lengthen, waiting lists shorten or retention improve? Each mechanism requires different management action and produces value for different people.

The trust bargain

Resistance becomes rational when the workforce expects efficiency to be punished. If every saved minute becomes another unit of demand, staff learn that innovation intensifies work. If an algorithm carries institutional authority but the clinician carries personal liability, “human oversight” becomes unpaid risk transfer. If a vendor captures recurring revenue while the provider supplies data, workflow expertise and verification, partnership becomes extraction.

Trust is therefore not a communications campaign. It is a forecast people make from institutional behaviour. It grows when commitments are specific, enforceable and honoured: protected learning time; no automatic headcount reduction during evaluation; transparent error reporting; shared governance; and a declared allocation of gains.

A STRONGER COMPACT

For the first year of a material AI deployment, pre-allocate the benefits: a defined share to patient access or quality, a share to workforce relief and capability, and a share to financial sustainability. Publish the allocation and report against it.

Demand can consume the gain

BCG highlights a second-order effect that many business cases omit: easier access can generate additional demand.[10] AI-enabled navigation, asynchronous consultation or continuous monitoring may uncover unmet need. That can be clinically desirable while increasing total workload and expenditure. A service can become more productive per encounter yet more expensive overall.

The correct question is therefore not simply “Does this save time?” but “What happens to the system when this becomes easier, cheaper or more available?” Capacity, demand and escalation must be modelled together.

Related Posts

on

21 Oct 2026

Why capable healthcare technology produces so little change - and how the people inside the system can alter the bargain

on

15 Oct 2026

What artificial intelligence really means for executive search in pharmaceuticals and biotechnology.

on

29 Aug 2026

In 2026, a group of AI agents did something nobody had programmed them to do. They organised themselves.

on

29 Aug 2026

A fact-checked analysis of the 2026 OpenAI/Hugging Face agent incident and its implications for leadership, business and society.

on

23 Aug 2026

A summary and critical appraisal of the New Scientist cover story and the supporting peer-reviewed evidence

on

7 Jul 2026

Appointment recognises Andy’s decade-long contribution to RSA, including team development, scientific expertise and role in building the firm’s West Coast business.

on

21 Oct 2026

Why capable healthcare technology produces so little change - and how the people inside the system can alter the bargain

on

15 Oct 2026

What artificial intelligence really means for executive search in pharmaceuticals and biotechnology.

on

29 Aug 2026

In 2026, a group of AI agents did something nobody had programmed them to do. They organised themselves.

on

29 Aug 2026

A fact-checked analysis of the 2026 OpenAI/Hugging Face agent incident and its implications for leadership, business and society.

Secure Your Next Life Science Leader

Move beyond generic search to provide a data-driven overview of your leadership's impact on clinical acceleration.

100%

Executive Retention ~12mo

5,600

Succesful Appointments

94%

Client Satisfacion Rate

6,800+

Subscribed Leaders & Executives

Life sciences advisory image representing specialist leadership search and clinical sector expertise.

United Kingdom

RSA Consulting Ltd & RSA Interims Ltd

The Gate House, Fretherne Road

Welwyn Garden City

Hertfordshire, AL8 6NS

+44 (0) 203 818 8820

hq@thersagroup.com


RSA Consulting Ltd (Company No: 01803896) and RSA Interims Ltd (Company No: 08433229), both registered in England and Wales.

Germany

RSA Consulting GmbH

Theodor-Heuss-Allee 112

60486 Frankfurt

+49 69 667741-470

hq@thersagroup.com


Represented by Nicholas D. Stephens, Kristian Juergensen


Registered in the Commercial Register (Handelsregister), Registration Court: District Court (Amtsgericht) Frankfurt am Main, Register Number: HRB 73074


German VAT Registration Number: VAT registration number according to § 27a of the German Value Added Tax Act (Umsatzsteuergesetz): DE 814 029 343

Singapore

The RSA Group Pte.Ltd

808 French Road

Kitchener Complex 

#07-163

Singapore 200808

+65 6 294 4588,

hq@thersagroup.com


Company EA Number: 07S5575.

Nicholas D. Stephens EA Registration Number: R1107308.

Switzerland

RSA AG

Hochbergerstrasse 70

4057 Basel

+41 61 563 0188

hq@thersagroup.com


Represented by Nicholas D. Stephens, Kristian Juergensen, Peter Dahinden


Swiss Register Entry & UID: Registered in the Commercial Register (Handelsregister), UID / Enterprise Identification Number: CHE-109.711.591

The RSA Group operates through RSA (Holdings) Ltd and its subsidiaries; RSA Consulting Ltd , RSA Interims Ltd , both registered in England and Wales and RSA Consulting GmbH, RSA AG and The RSA Group Pte.Ltd. Registered Office for RSA Holding is: The Gate House, Fretherne Road, Welwyn Garden City, Hertfordshire, AL8 6NS. The RSA Group is a premier global executive search, interim / fractional leadership and advisory firm specialising exclusively in the Life Sciences sector, dedicated to uniting leadership with innovation-driven organisations to accelerate the discovery and delivery of therapies. Registered with the Information Commissioner’s Office (ICO) in full compliance with the Data Protection Act 2018 and UK GDPR.